Santaris Pharma A/S Obtains Exclusive License From Mass General Hospital For Intellectual Property Related To The Regulation Of MiR-33 For The Treatment Of Cardiovascular Disorders
HOERSHOLM, Denmark and SAN DIEGO, February 28, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA…